CarboCode, known as The glycosphingolipid company, is focused on advancing human health, emphasizing biotechnology innovations. Founded in 2017 and headquartered in Portugal, the company unites top-tier scientists from various disciplines to pioneer in human sphingolipid production.
By combining their expertise in biotechnology, enzyme technology, and chemistry, CarboCode has established a research center in Germany while strategically partnering with a development and manufacturing team in Portugal to ensure scalable and cost-effective production.
CarboCode targets the skincare and infant nutrition sectors with evidence-backed applications, promoting skin health and cognitive and nutritional benefits. Despite having no recent recorded investments, the company's commitment to scientific innovation positions it as a promising candidate for future funding opportunities in the rapidly growing field of health biotechnology.